Cadila Healthcare has informed that the Company’s Topical manufacturing facility located at Changodar, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in March 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant.
The above information is a part of company’s filings submitted to BSE.